Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
4 findings from 1 review
Show 1 more finding
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower adverse effects: EPS: unspecified ‐ Versus high dose (greater than… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Effects of non-stevia high-intensity sweeteners (aspartame, sucralose, saccharin) on cariogenic bacteria in dental plaque or saliva · healthy people
No eligible studies evaluated high-intensity sweeteners such as aspartame, sucralose, or saccharin for their effect on cariogenic bacteria.
1 finding from 1 review
Mortality Median · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate showed no clear difference in mortality (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Progression/relapse · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate probably leads to lower progression/relapse (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Treatment‐related mortality · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with primary CNS lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse effects (grade 3+): Infection · patients with primary CNS lymphoma
Cytarabine plus high‐dose methotrexate probably leads to higher infections (grade 3 to 4) compared with high‐dose methotrexate alone (moderate certainty).
1 finding from 1 review
Live birth rate per woman · women undergoing assisted reproduction
It is very uncertain whether higher changes live birth per woman randomised: sensitivity analysis (including all… compared with lower degree of injury (very low certainty).
1 finding from 1 review
Miscarriage · women undergoing assisted reproduction
It is very uncertain whether higher changes miscarriage per woman randomised: sensitivity analysis (including… compared with lower degree of injury (very low certainty).
1 finding from 1 review
Clinical pregnancy · women undergoing assisted reproduction
It is very uncertain whether higher changes clinical pregnancy per woman randomised: sensitivity analysis… compared with lower degree of injury (very low certainty).
1 finding from 1 review
Smoking cessation · tobacco smokers (general population, hospital inpatients with mixed diagnoses)
Higher may leads to higher smoking cessation at ≥ 6 months compared with lower intensity motivational interviewing (low certainty).
1 finding from 1 review
All‐cause mortality Study duration range 12‐96 months Omega‐6 dose range 1.5%‐24.5% E · adults with or without existing CVD
Higher showed no clear difference in all‐cause mortality Study duration range 12‐96 months Omega‐6 dose… compared with lower omega‐6: primary outcomes (low certainty).
1 finding from 1 review
LDL Study duration range 12‐24 months Omega‐6 dose range 2.0%‐15.0% E · adults with or without existing CVD
1 finding from 1 review
HDL Study duration range 12‐24 months Omega‐6 dose range 2.0%‐15.0% E · adults with or without existing CVD
1 finding from 1 review
Weight (kg) · adults with or without existing CVD
1 finding from 1 review
Body‐mass index (BMI) · adults with or without existing CVD
1 finding from 1 review
Cardiovascular mortality · adults with or without existing CVD
It is very uncertain whether higher changes cardiovascular mortality Study duration range 24‐96 months Omega‐6… compared with lower omega‐6: primary outcomes (very low certainty).
1 finding from 1 review
Cardiovascular events · adults with or without existing CVD
Higher showed no clear difference in cardiovascular events: any Study duration range 12‐96 months Omega‐6… compared with lower omega‐6: primary outcomes (low certainty).
1 finding from 1 review